Approval · Notice of Compliance 26559 · 2021
LENALIDOMIDE: Notice of Compliance 26559
Issued September 1, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26559
- Date
- September 1, 2021
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- REVLIMID (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LENALIDOMIDE | 02493926 | Cancelled Pre Market |
| LENALIDOMIDE | 02493934 | Cancelled Pre Market |
| LENALIDOMIDE | 02493942 | Cancelled Pre Market |
| LENALIDOMIDE | 02493950 | Cancelled Pre Market |
| LENALIDOMIDE | 02493969 | Cancelled Pre Market |
| LENALIDOMIDE | 02493977 | Cancelled Pre Market |
| LENALIDOMIDE | 02493985 | Cancelled Pre Market |
Medicinal ingredients
- LENALIDOMIDE 2.5 MG per TAB
- LENALIDOMIDE 5 MG per TAB
- LENALIDOMIDE 7.5 MG per TAB
- LENALIDOMIDE 10 MG per TAB
- LENALIDOMIDE 15 MG per TAB
- LENALIDOMIDE 20 MG per TAB
- LENALIDOMIDE 25 MG per TAB